IN8bio EVP granted 54,000 stock options

IN8BIO, INC. executive Lawrence Lamb, EVP and CSO, received an employee stock option grant covering 54,000 shares of common stock.

Rhea-AI Filing Summary

IN8BIO, INC. executive Lawrence Lamb, EVP and CSO, received an employee stock option grant covering 54,000 shares of common stock. The option has an exercise price of $1.58 per share and expires on May 9, 2036. After this grant, Lamb holds options for 54,000 shares directly.

According to the vesting terms, 25% of the option shares vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to Lamb continuing to provide service through each vesting date.

Insider Trade Summary

Grant/Award: 54,000 shares

Grant/Award 1 txn

Insider Lamb Lawrence

Role EVP and CSO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	54,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 54,000 contracts (Direct)

Footnotes (1)

1. F1. Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date.

Key Figures

Option grant size: 54,000 shares Exercise price: $1.58 per share Shares underlying option: 54,000 shares +3 more

6 metrics

Option grant size 54,000 shares Employee stock option covering common stock

Exercise price $1.58 per share Stock option exercise price

Shares underlying option 54,000 shares Underlying common stock tied to the option

Expiration date May 9, 2036 Option expiration

First vesting date November 9, 2026 25% of option vests

Final vesting date May 9, 2028 Remaining 25% of option vests

Key Terms

Employee Stock Option (right to buy), exercise price, expiration date, vesting

4 terms

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 1.5800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-09T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IN8bio (INAB) executive Lawrence Lamb report in this Form 4?

Lawrence Lamb, EVP and CSO of IN8bio, reported receiving an employee stock option grant for 54,000 shares of common stock at a $1.58 exercise price, expiring May 9, 2036, as part of his compensation package.

How many IN8bio (INAB) stock options were granted to Lawrence Lamb?

Lawrence Lamb was granted options covering 54,000 shares of IN8bio common stock. These options are held directly and give him the right to buy shares at a fixed $1.58 exercise price before the stated expiration date in 2036.

What is the exercise price of Lawrence Lamb’s IN8bio (INAB) stock options?

The stock options granted to Lawrence Lamb have an exercise price of $1.58 per share. This means he can purchase IN8bio common stock at $1.58 per share once the options vest, any time before they expire on May 9, 2036.

When do Lawrence Lamb’s IN8bio (INAB) stock options vest?

The options vest in four equal 25% installments on November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028. Vesting on each date depends on Lamb continuing to provide service to IN8bio through that vesting date.

Is Lawrence Lamb’s IN8bio (INAB) Form 4 transaction a market purchase or sale?

The Form 4 reports a grant of employee stock options, not a market trade. The transaction is coded as an acquisition (grant or award), giving Lamb the right to buy 54,000 shares at $1.58, rather than reflecting open-market buying or selling.

What is the expiration date of Lawrence Lamb’s IN8bio (INAB) stock options?

The employee stock options granted to Lawrence Lamb expire on May 9, 2036. He may exercise vested portions of the 54,000-share option at the $1.58 exercise price any time up to that expiration date, subject to applicable plan terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lamb Lawrence

(Last) (First) (Middle)

C/O IN8BIO, INC.

350 5TH AVE. SUITE 5330

(Street)

NEW YORK NEW YORK 10118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IN8BIO, INC. [ INAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CSO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.58	05/09/2026		A		54,000		(1)	05/09/2036	Common Stock	54,000	$0	54,000	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date.

	/s/ William Ho, Attoney-in-Fact	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)